Cancer cells alter metabolic processes to sustain their characteristic uncontrolled growth
and proliferation. These metabolic alterations include (1) a shift from oxidative …

Fluorouracil (5-FU) is an essential component of systemic chemotherapy for colorectal
cancer (CRC) in the palliative and adjuvant settings. Over the past four decades, several …

Colorectal cancer (CRC) is a leading cause of death worldwide, despite progress made in
detection and management through surgery, chemotherapy, radiotherapy, and …

Cancer cells characterized by uncontrolled growth and proliferation require altered
metabolic processes to maintain this characteristic. Metabolic reprogramming is a process …

Despite many studies of the likely survival outcome of individual patients with colorectal
cancer, our knowledge of this subject remains poor. Until recently, we had virtually no …

Purpose Fluourouracil (FU) is a mainstay of chemotherapy, although toxicities are common.
Genetic biomarkers have been used to predict these adverse events, but their utility is …

Background: Fluoropyrimidine drugs are extensively used for the treatment of solid cancers.
However, adverse drug reactions are a major clinical problem, often necessitating treatment …

During the past two decades the first sequencing of the human genome was performed
showing its high degree of inter-individual differentiation, as a result of large international …

Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) and approved for treatment of
various malignancies. Hereditary genetic variants may affect a drug's pharmacokinetics or …

Pharmacogenetics represents an exciting, new promising tool for the individualisation of
therapy. Several genetic polymorphisms and haplotypes have been considered in an …